Long Acting Injectables Market Size, Share, and Industry Analysis, By Molecule Type (Small Molecules, Biologics, Peptides/Hormones, and Others), By Delivery System (Depot Injections, Microspheres, Implants, Oil-based Injections, and Others), By Therapeutic Area (Psychiatry, Endocrinology/Diabetes, Oncology, Infectious Diseases, Contraception, and Others), By Distribution Channel (Hospitals, Specialty Clinics, Drug Stores & Retail Pharmacies, and Others), and Regional Forecast till 2034

The global long acting injectables market was valued at USD 32.00 billion in 2025. The market is projected to grow from USD 35.07 billion in 2026 to USD 73.00 billion by 2034, exhibiting a CAGR of 9.6% during the forecast period.

The product demand is gaining momentum as pharmaceutical companies focus on improving treatment adherence, reducing dosing frequency, and supporting better long-term disease management. Long-acting injectable formulations are designed to release medicines slowly over weeks or months, which helps reduce the burden of daily or frequent dosing for patients. These characteristics are important in therapy areas such as schizophrenia, bipolar disorder, HIV treatment and prevention, opioid use disorder, contraception, hormone therapy, and oncology supportive care, where missed doses can affect treatment outcomes. As companies continue to invest in depot formulations, sustained-release technologies, prefilled delivery systems, and longer-duration injectable therapies, the market is expected to strengthen across both mature and emerging healthcare systems.

• For instance, in January 2025, ViiV Healthcare received marketing authorization from the European Commission for its long-acting injectable Vocabria, used for HIV-1 treatment in adolescents aged 12 years and older who are virologically suppressed. These developments are expected to reduce dependence on daily oral therapy and strengthen the commercial role of injectable regimens in chronic disease management.

Furthermore, funding initiatives, research and development, strategic partnerships, and new product launches by key operating companies strengthen their market position and support market growth.

Long Acting Injectables Market Driver

Rising Need to Improve Patient Adherence in Chronic Disease Treatment to Drive Market Growth

The global market is growing as chronic disease treatment often requires patients to stay on therapy for many months or years. Long acting injectables facilitate this long-term adherence. They maintain drug levels for weeks or months after a single administration, which reduces the burden of daily tablets and supports better adherence. This is especially important in disease areas where treatment gaps can increase the risk of relapse, disease progression, or reduced clinical effectiveness. As healthcare providers focus more on long-term outcomes and fewer interruptions in care, the demand for long-acting injectable formulations is expected to increase steadily. These advantages have prompted key companies to focus on the development of injectables through research and development.

• For instance, in July 2025, ViiV Healthcare announced data from the Phase IIIb VOLITION study showcasing that 89% of eligible treatment-naïve people living with HIV chose to switch from daily pills to long-acting injectable Vocabria + Rekambys after achieving rapid viral suppression. The study also reported implementation data showing that 95% of participants switched from oral PrEP to long-acting injectable Apretude, highlighting how reduced dosing frequency can support patient preference and adherence in chronic HIV care.

Download Free sample to learn more about this report.

In 2024, the British Journal of General Practice (BJGP) Open study conducted a survey titled ‘Chronic Disease Medication Management at Home: A Quantitative Survey among 180 Patients.’ The study found that more than half of patients were non-adherent to oral medication for long-term conditions, and 61% of respondents reported forgetting to take their medication, compared to only 39% who said they never forgot.

Long Acting Injectables Market Restraint

High Development and Manufacturing Costs Limiting Product Affordability May Restrain Market Growth

The global market expansion is restrained due to the high cost involved in developing and manufacturing these products. Unlike oral drugs, long acting injectables require complex depot technologies, sterile manufacturing, controlled-release formulation expertise, specialized filling lines, and strict quality testing to ensure that the drug is released safely over weeks or months. Due to this, companies need higher investment in formulation development, clinical validation, manufacturing scale-up, and regulatory compliance, elevating the final product cost. As a result, even though long acting injectables offer strong clinical value, their adoption can remain slower due to limited affordability.

• For instance, in October 2024, Camurus received a Complete Response Letter from the U.S. FDA for CAM2029, its octreotide extended-release injection for acromegaly, due to facility-related deficiencies identified during a cGMP inspection of a third-party manufacturer. It stated that the CRL raised concerns related to the approval still depending on satisfactory resolution of manufacturing-site deficiencies. It was due to complex sterile manufacturing and third-party facility compliance requirements that can delay long-acting injectable approvals, increase development timelines, and add cost pressure for companies trying to commercialize injectable products.

Long Acting Injectables Market Opportunity

Rising Pipeline of Next-Generation Depot and Sustained-Release Formulations to Create Strong Market Growth Opportunities

The global market depicts strong growth opportunities as companies are moving toward next-generation sustained-release products. These products have longer dosing intervals, easier administration, and broader therapeutic use. Many chronic diseases require continuous drug exposure, but frequent dosing can reduce patient adherence and increase the burden on healthcare systems. As a result, pharmaceutical companies are investing in advanced polymer-based depots, subcutaneous long-acting platforms, and extended-release injectable technologies that can support monthly, two-monthly, or even longer treatment schedules. Therefore, a growing pipeline of next-generation depot and sustained-release formulations is expected to create new revenue opportunities and support wider market adoption.

• For instance, in September 2025, Teva Pharmaceutical, in collaboration with MedinCell, announced new long-term Phase 3 SOLARIS data for TEV-’749, an investigational subcutaneous long-acting injectable olanzapine for schizophrenia. Such developments are anticipated to offer growth opportunities.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Key Disease Indications, By Key Regions/Countries
• Key Industry Developments (Strategic Partnerships, Acquisitions, and Mergers)
• Overview of Regulatory Scenario, By Key Countries/Regions
• New Product Launches, By Key Players

Analysis by Molecule Type

Based on molecule type, the global long acting injectables market is segmented into small molecules, biologics, peptides/hormones, and others.

Among these, the small molecules segment is estimated to dominate the global market. A high share is allocated to the segment as many of the highest-selling long-acting injectable products are based on small-molecule drugs used in psychiatry, HIV, opioid use disorder, and hormone-related treatment. These molecules are generally easier to formulate into depot or extended-release injectable systems compared to large biologics, which helps companies develop multiple dosing intervals and broader product portfolios. As a result, the strong commercial base of long-acting antipsychotics and newer small-molecule HIV injectables continues to drive the dominance of the segment.

• For instance, in June 2025, Gilead Sciences received approval from the U.S. FDA for Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as an HIV prevention option in the U.S. This supported the dominance of small molecules by molecule type.

Analysis by Delivery System

Based on delivery system, the global long acting injectables market is segmented into depot injections, microspheres, implants, oil-based injections, and others.

The depot injections segment is expected to dominate the market. The segment is allocated a high share as they are the most established and commercially proven delivery system for long-acting injectable therapies. These formulations create a drug reservoir in the body and release the active ingredient slowly over weeks or months, reducing dosing frequency while maintaining continuous therapeutic exposure. Depot systems are widely used in schizophrenia, bipolar disorder, prostate cancer, endometriosis, acromegaly, and opioid use disorder, giving them a wider therapy area base.

• For instance, in November 2025, AbbVie announced that a new 6-month 45 mg LUPRON DEPOT strength received Health Canada approval for the treatment of advanced prostate cancer.

Owing to such developments, the segment continues to expand through longer-duration strengths, supporting convenience for patients and strengthening the commercial relevance of depot-based long acting injectables.

Analysis by Therapeutic Area

Based on therapeutic area, the market is segmented into psychiatry, endocrinology/diabetes, oncology, infectious diseases, contraception, and others.

The psychiatry segment is likely to dominate the global market. Schizophrenia and bipolar disorder require long-term treatment continuity, but missed daily doses are common and can lead to relapse, hospitalization, and higher healthcare costs. Long-acting antipsychotics help address this issue and reduce dependence on daily patient behavior. The segment also benefits from strong branded portfolios from companies to combine high unmet adherence need, chronic treatment duration, and multiple established LAI brands.

• For instance, in September 2021, Johnson & Johnson received approval from the U.S. FDA for INVEGA HAFYERA, a 6-month paliperidone palmitate injection and the first twice-yearly treatment for adults with schizophrenia. The approval was supported by Phase 3 data showing more than 92% of participants were relapse-free at 12 months, highlighting why long-acting antipsychotics remain central to the market.

Analysis by Distribution Channel

Based on distribution channel, the market is segmented into hospitals, specialty clinics, drug stores & retail pharmacies, and others.

The hospitals segment accounts for the largest share. Many long acting injectables require healthcare professional administration, patient monitoring, cold-chain handling, specialty storage, and structured follow-up. Hospitals also manage a large share of patients with schizophrenia relapse risk, oncology-related hormone therapy needs, advanced endocrine disorders, and infectious disease treatment requirements, making them key points of use for high-value injectable therapies. As a result, hospitals remain the leading end-user channel.

• For instance, in April 2023, Otsuka and Lundbeck announced the U.S. FDA approval of ABILIFY ASIMTUFII, the first once-every-two-months long-acting injectable for schizophrenia and maintenance monotherapy treatment of bipolar I disorder in adults. The product is an intramuscular extended-release injectable, which reinforces the role of hospital and clinic-based healthcare professionals in administering and monitoring long-acting psychiatric therapies.

Regional Analysis

Request for Customization   to gain extensive market insights.

On the basis of region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for approximately 42.0% of the global long acting injectables market in 2025. The market is showing strong growth in North America as the region has high adoption of specialty medicines, strong access to advanced injectable therapies, and a large treated patient base across psychiatry, HIV, oncology, opioid use disorder, and hormonal disorders. Healthcare providers in the region are increasingly using long-acting formulations to reduce missed doses, improve treatment continuity, and lower relapse-related healthcare costs. The region also benefits from faster regulatory uptake, stronger reimbursement for branded specialty injectables, and wider availability of hospital, clinic, and specialty pharmacy infrastructure.

• For instance, in June 2025, Gilead Sciences received U.S. FDA approval for Yeztugo (lenacapavir), a twice-yearly injectable HIV prevention option in the U.S.

The Europe market is expected to grow at a significant CAGR during the forecast period. The market is growing in Europe as these therapies reduce treatment burden, improve adherence, and support better chronic disease management. In addition, regulatory approvals across the European Commission can open access across multiple EU markets, helping companies scale products more efficiently.

• For instance, in January 2025, ViiV Healthcare received marketing authorization from the European Commission for long-acting injectable Vocabria, used for HIV-1 treatment in adolescents aged 12 years and older and weighing at least 35 kg.

The Asia Pacific long acting injectables market is expected to grow at a stable CAGR during the forecast period. The regional market is growing as the region has a large chronic disease population, rising healthcare spending, and increasing demand for therapies that reduce frequent hospital visits and improve adherence. As multinational and regional pharmaceutical companies increase regulatory filings, clinical programs, and commercial launches in the Asia Pacific, the region is expected to become one of the fastest-growing markets.

• For instance, in July 2025, Gilead Sciences announced new data on twice-yearly lenacapavir for HIV prevention and stated that it had filed for regulatory approval with authorities in Australia. These factors support growth in the Asia Pacific region as Australia is one of the region’s advanced launch markets and approval filings for twice-yearly injectable PrEP show how next-generation long-acting products are expanding beyond the U.S. and Europe into the Asia Pacific.

Key Players Covered

The global long acting injectables market is semi-consolidated, with a few players capturing significant market share and other small players retaining the remaining market share.

The report includes the profiles of the following key players.

• Johnson & Johnson Services, Inc. (U.S.)
• GSK plc (U.K.)
• Otsuka Pharmaceutical Co., Ltd. (Japan)
• AbbVie Inc. (U.S.)
• Ipsen Pharma (France)
• Novartis AG (Switzerland)
• Alkermes plc (Ireland)
• Indivior PLC (U.S.)
• Gilead Sciences, Inc. (U.S.)
• Tolmar Pharmaceuticals, Inc. (U.S.)

Key Industry Developments

• October 2025: Lupin Limited launched a partnership program aimed at expanding the reach of PrecisionSphere, the long-acting injectable (LAI) platform. PrecisionSphere demonstrated efficacy and safety in drug delivery.
• December 2024: Neuraxpharm Group, a leading pharmaceutical company focused on the development and supply of long-acting injectable (LAI) therapies, partnered with Pharmathen to co-develop new long-acting injectable therapies within the psychiatry field.